Osman obtained his MD from the University of Glasgow and his MPH from Johns Hopkins. He is a Board-Certified nephrologist with a passion for Home Dialysis. He is an experienced Clinical researcher and entrepreneur who has run several businesses in the Dialysis industry including a Clinical Research company and several Dialysis Units in San Diego. He currently serves on the Palomar Health Foundation Board.
A 20-year veteran of the medical device and pharmaceutical industries, Dan most recently was Chief Commercial Officer for Neuronetics from 2018 to 2020. Following a successful IPO in 2018, Dan grew the commercial organization over 18 months to secure the company’s market leadership within the category. Before Neuronetics, he held senior commercial roles at JADAK, Zimmer Biomet, Medtronic and Fleet Laboratories. Dan earned his bachelor’s degree in finance and marketing from American University and his MBA from Southern Illinois University at Carbondale.
Jahnavi obtained her MS from Texas A&M and her MBA from UCLA. She is a very experienced product developer. She previously worked at Sparton, a contract manufacturing and design company as a General manager of the Irvine office. There she oversaw a multitude of electromechanical and software medical devices and brings a depth of experience in medical devices.
Clayton is an experienced systems engineer and technical manager who worked on the first home hemodialysis machine at Aksys Ltd. Clayton received his BS in Mechanical Engineering from Duke University, and both his MS in Systems Engineering and MBA from MIT. Clayton leads the engineering team and is excited to be developing the best dialysis machine in the industry.
Pam has over 30 years of highly diversified financial experience, primarily in the biotech and pharmaceutical industries. At Amgen Corporation she raised over $6bn of financing in the capital markets and led prioritization of spending decisions for Amgen’s $3bn R&D budget. She then served as Chief Financial Officer for True North Therapeutics and later for Graybug Vision. At True North, she raised $45M in Series D financing and led the preparation for an IPO prior to the sale of True North to Bioverativ. At Graybug Vision, she raised $55M Series C and completed multiple years of audits. Most recently, Pam served as Chief Financial Officer of Capsida Biotherapeutics. Pam holds a BA from Wellesley College and an MBA from Columbia University.